G

Genedrive PLC
LSE:GDR

Watchlist Manager
Genedrive PLC
LSE:GDR
Watchlist
Price: 2.4 GBX -2.04% Market Closed
Market Cap: 13m GBX
Have any thoughts about
Genedrive PLC?
Write Note

Genedrive PLC
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genedrive PLC
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
G
Genedrive PLC
LSE:GDR
Total Current Liabilities
ÂŁ1.9m
CAGR 3-Years
15%
CAGR 5-Years
7%
CAGR 10-Years
3%
Oxford Nanopore Technologies PLC
LSE:ONT
Total Current Liabilities
ÂŁ89.2m
CAGR 3-Years
7%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Total Current Liabilities
ÂŁ2.6m
CAGR 3-Years
-4%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Total Current Liabilities
ÂŁ37.3m
CAGR 3-Years
1%
CAGR 5-Years
24%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Total Current Liabilities
ÂŁ1.6m
CAGR 3-Years
10%
CAGR 5-Years
5%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Total Current Liabilities
ÂŁ36m
CAGR 3-Years
24%
CAGR 5-Years
51%
CAGR 10-Years
40%
No Stocks Found

Genedrive PLC
Glance View

Market Cap
13m GBX
Industry
Life Sciences Tools & Services

Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The Company’s Genedrive device is a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company’s commercial products include Genedrive MT-RNR1, Genedrive BioPlex, Genedrive HCV ID Kit and Genedrive 96 SARS-CoV-2 Ki. Genedrive MT-RNR1 is a commercial test for antibiotic induced hearing loss. Genedrive BioPlex is developed for the determination of military biothreats from pathogens. Genedrive HCV ID Kit is effective in the diagnosis of Hepatitis C Virus (HCV) infection in resource limited settings. Genedrive 96 SARS-CoV-2 Ki is a plate format of a COVID-19 molecular test for high throughput use, which detects all known variants of COVID-19.

GDR Intrinsic Value
0.41 GBX
Overvaluation 83%
Intrinsic Value
Price
G

See Also

What is Genedrive PLC's Total Current Liabilities?
Total Current Liabilities
1.9m GBP

Based on the financial report for Dec 31, 2023, Genedrive PLC's Total Current Liabilities amounts to 1.9m GBP.

What is Genedrive PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
3%

Over the last year, the Total Current Liabilities growth was 50%. The average annual Total Current Liabilities growth rates for Genedrive PLC have been 15% over the past three years , 7% over the past five years , and 3% over the past ten years .

Back to Top